Free Trial

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

-0.23 (-2.37%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
220,316 shs
Average Volume
450,470 shs
Market Capitalization
$245.63 million
P/E Ratio
Dividend Yield
Price Target

Inovio Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
645.4% Upside
$70.67 Price Target
Short Interest
7.28% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.96mentions of Inovio Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($4.50) to ($3.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

202nd out of 913 stocks

Surgical & Medical Instruments Industry

30th out of 100 stocks

INO stock logo

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Stock Price History

INO Stock News Headlines

Inovio: Q1 Earnings Snapshot
Inovio Pharmaceuticals earnings: here's what Wall Street expects
See More Headlines
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.16 per share


Free Float
Market Cap
$245.63 million

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Jacqueline E. Shea Ph.D. (Age 58)
    CEO, President & Director
    Comp: $1.13M
  • Mr. Peter D. KiesMr. Peter D. Kies (Age 61)
    Chief Financial Officer
    Comp: $810.2k
  • Dr. Laurent M. Humeau Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $794.08k
  • Thomas Hong
    Manager of Investor Relations
  • Mr. Robert L. Crotty J.D. (Age 50)
    General Counsel & Chief Compliance Officer
  • Mr. E. J. Brandreth MBA
    Senior Vice President of Quality Assurance
  • Dr. Jeffrey Skolnik
    Senior Vice President of Clinical Development
  • Mr. Robert J. Juba Jr.
    Senior Vice President of Biological Manufacturing & Clinical Supply Management
  • Mr. Stephen Kemmerrer M.B.A.
    P.E., Senior Vice President of Engineering Development
  • Mr. Shawn D. Bridy M.A.
    M.B.A., Senior Vice President of Business Development

INO Stock Analysis - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" INO shares.
View INO analyst ratings
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month price objectives for Inovio Pharmaceuticals' stock. Their INO share price targets range from $20.00 to $144.00. On average, they anticipate the company's stock price to reach $70.67 in the next year. This suggests a possible upside of 645.4% from the stock's current price.
View analysts price targets for INO
or view top-rated stocks among Wall Street analysts.

How have INO shares performed in 2024?

Inovio Pharmaceuticals' stock was trading at $73.44 at the beginning of the year. Since then, INO stock has decreased by 87.1% and is now trading at $9.48.
View the best growth stocks for 2024 here

Are investors shorting Inovio Pharmaceuticals?

Inovio Pharmaceuticals saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 1,870,000 shares, a decline of 12.6% from the May 15th total of 2,140,000 shares. Based on an average daily volume of 384,600 shares, the days-to-cover ratio is currently 4.9 days. Approximately 7.3% of the company's shares are short sold.
View Inovio Pharmaceuticals' Short Interest

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our INO earnings forecast

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings data on Monday, May, 13th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by $0.23. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 88.13% and a negative net margin of 16,238.91%. During the same quarter in the prior year, the business posted ($1.92) EPS.

What ETFs hold Inovio Pharmaceuticals' stock?

ETFs with the largest weight of Inovio Pharmaceuticals (NASDAQ:INO) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).Amplify Treatments, Testing and Advancements ETF (GERM).

When did Inovio Pharmaceuticals' stock split?

Shares of Inovio Pharmaceuticals reverse split on the morning of Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.82%), Susquehanna Fundamental Investments LLC (0.46%), GSA Capital Partners LLP (0.34%), Green Alpha Advisors LLC (0.16%), Simplex Trading LLC (0.00%) and Jacobs Levy Equity Management Inc. (0.07%). Insiders that own company stock include David B Weiner and Simon X Benito.
View institutional ownership trends

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INO) was last updated on 6/13/2024 by Staff

From Our Partners